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Summary 
Epilepsy is one of the commonest serious neurological conditions. It is characterized by the 
tendency to have recurrent seizures, which arise against a backdrop of apparently normal brain 
activity. At present, clinical diagnosis relies on: (i) case history, which can be unreliable; (ii) 
observing transient abnormal activity during electroencephalography (EEG), which may not be 
present during clinical evaluation; (iii) if diagnostic uncertainty occurs, undertaking prolonged 
monitoring in an attempt to observe EEG abnormalities, which is costly. Herein, we describe the 
discovery and validation of an epilepsy biomarker based on computational analysis of a short 
segment of resting-state (inter-ictal) EEG. Our method utilizes a computer model of dynamic 
networks, where the network is inferred from the extent of synchrony between EEG channels 
(functional networks) and the normalized power spectrum of the clinical data. We optimize model 
parameters using a leave-one-out classification on a dataset comprising 30 people with idiopathic 
generalized epilepsy (IGE) and 38 normal controls. Applying this scheme to all 68 subjects we find 
100% specificity at 56.7% sensitivity, and 100% sensitivity at 65.8% specificity. We believe this 
biomarker could readily provide additional support to the diagnostic process. 
 
 
 
Introduction 
 
At present a confirmed diagnosis of epilepsy is made through a case history and a positive EEG, 
confirming the presence of epileptiform discharges. However, a positive EEG occurs at best in only 
60% of cases, resulting in diagnostic uncertainty for many people1, with significant associated 
costs2. These costs predominantly result from additional longer-term EEG monitoring, repeated 
hospital admissions, as well as unnecessary prescription of anti-epilepsy drugs.  
 
Idiopathic generalized epilepsy (IGE) is one of the main classes of epilepsy. In recent years, studies 
comparing cohorts of people with IGE and cohorts of healthy controls have shown statistically 
significant alterations at the group level when examining resting-state features of the EEG using 
power spectrum3, functional networks4 and a model-driven analysis of functional networks5. 
However, substantial overlap of these markers between groups may render the measurement 
unsuitable as a diagnostic test or biomarker6 for any one individual. Our aim therefore is to assess 
the performance of each of these methods as a classifier that has three outcomes for each individual: 
unequivocally IGE, unequivocally normal, or uncertain. Such a classifier could be used as a 
screening test in a non-specialist primary care setting, as well as a diagnostic validation test in a 
specialist epilepsy setting. This would focus further medical investigation and resources on a 
smaller subgroup, producing efficiency gains and cost savings. 
 
Methods 
 
We studied data from 38 healthy controls and 30 people with IGE aged between 16 and 59. The 
individuals with IGE were drug naïve and recruited through clinics at St Thomas’s Hospital. A 
diagnosis of epilepsy was confirmed in each case by an experienced epilepsy specialist through 
observation of typical generalized spike-wave (GSW) activity on EEG either spontaneously or 
following hyperventilation or photic stimulation. For 10 of these people the diagnosis was 
confirmed following an initial routine EEG. For the remaining 20, diagnosis was confirmed 
following sleep-deprived or longer-term EEG monitoring (including sleep). Similar healthy control 
EEG was collected at King’s College Hospital EEG department. Controls gave written informed 
consent and data collection was approved by King’s College Hospital Research Ethics Committee 
(08/H0808/157). Under UK law, patient data collected during normal clinical routine and 
anonymized before research use may be used for research without additional consent; this 
procedure was reviewed and approved for this project by St Thomas’s Hospital and King’s College 
Hospital’s Research and Development departments. 
 
A trained clinical EEG technician identified a 20-second long, GSW and artifact free, segment of 
eyes-closed “resting state” EEG activity from the initial stage of the recordings from each 
participant. These data were band-pass filtered using a Butterworth filter between 0.5 and 70Hz, 
and band-stop filtered between 48 and 52Hz to remove power-line artifacts. Since signal amplitude 
may vary between individuals due to different anatomical features (such as the size and shape of the 
cranium) the data were normalized by dividing the power spectrum in each channel by the total 
power in the spectrum averaged across all channels. This normalized power preserves relative 
differences in power between channels. We then band-pass filtered the EEG segments into either 
the alpha (8-13Hz) or low alpha bands7 (6-9Hz). For segments band-pass filtered in the low alpha 
band, we further inferred functional networks using the Phase-Locking Factor8 (PLF) and phase-
lags (as previously described)5.  
 
For the purpose of biomarker discovery, we consider measures that have demonstrated group-level 
differences between people with IGE and healthy controls using resting-state EEG. First, the peak 
in alpha power across occipital EEG channels, which is known to shift towards lower frequencies 
in people with IGE3. Second, the mean-degree of the PLF-inferred low alpha functional network, 
which is elevated in people with IGE4. Third, a model-driven analysis where the low alpha 
functional network inferred from the EEG of each individual is integrated within a phase oscillator 
model (of Kuramoto type)5. Here the local coupling constant within each node of the network is 
inferred by multiplying the variance of the signal in the corresponding EEG channel by a uniform 
parameter K, to give a subject-specific dynamic network model of the brain. The seizure-generating 
capability of each region within this model is then evaluated computationally, as the average level 
of emergent seizure activity across the whole network driven by the region of interest (see Fig. 1A).  
 
The performance of all three candidate biomarkers was evaluated using “leave-one-out” 
classification9, in which all 30 people with IGE and 38 controls are pooled, the data from one 
subject is successively left aside and the remaining data used as the training set. In each case, 
thresholds are determined to give the highest sensitivity for 100% specificity and the highest 
specificity for 100% sensitivity in the training set. In turn, these thresholds are applied to classify 
the test subject as follows: If the value of local coupling is on the IGE side of both thresholds, then 
the individual is classified as unequivocally having epilepsy. The individual is classified as 
unequivocally normal if their value is on the control side of both thresholds. If their value lies 
between these thresholds they are classified as uncertain. A graphical representation of this 
approach is shown in Fig. 1B. Since each outcome is discrete and non-normal, we use the Friedman 
test10 (non-parametric repeated measures ANOVA) to assess the relative performance of each 
biomarker. 
 
Results 
 
Successively optimizing the channel location and value of the local coupling constant to give the 
highest levels of sensitivity and specificity in each training set, the local coupling biomarker 
resulted in 56.7% sensitivity (given 100% specificity) and 65.8% specificity (given 100% 
sensitivity). Specifically, 17 of 30 people with IGE were classified as unequivocally having 
epilepsy, 10 received an uncertain classification, and three were misclassified. Of the 38 healthy 
controls, 25 were correctly classified and 13 received an uncertain classification. 
 
In contrast, average power of the EEG power spectrum and the mean degree of the inferred 
functional network performed poorly with low sensitivity and specificity. The peak in alpha power 
resulted in 0% sensitivity (given 100% specificity) and 0% specificity (given 100% sensitivity). It 
classified no people with IGE as having epilepsy, 29 were classified as uncertain, and one was 
misclassified. Of the 38 healthy controls, 0 were correctly classified, 37 received an uncertain 
classification and one was misclassified. Mean degree resulted in 3.3% sensitivity (given 100% 
specificity) and 15.8% specificity (given 100% sensitivity). It classified one person with IGE as 
having epilepsy, 28 were classified as uncertain, and one was misclassified. Of the 38 health 
controls, 6 were correctly classified, 31 received an uncertain classification and one was 
misclassified.  
 
The Friedman test confirms that the classification results of the local coupling biomarker are 
statistically significant for people with IGE (chi-squared = 26.77, p<0.001) and controls (chi-
squared = 22.83, p<0.001) in comparison to the other potential biomarkers. Using pairwise 
comparison, we show that the local coupling performs consistently better than either average power 
(IGE: chi-squared = 14.22, p<0.001; controls: chi-squared = 7.14, p = 0.007) or mean degree (IGE: 
chi-squared = 13.24, p<0.001; controls: chi-squared = 19.17, p<0.001). 
 
Discussion 
 
Herein we describe the comparative analysis of three candidate biomarkers of IGE using 20s 
segments of “resting-state” EEG from cohorts of drug-naïve people with IGE and age- and gender-
matched healthy controls. To our knowledge these three candidates are the only published methods 
to date that have shown statistically significant differences at the group level using “resting-state” 
EEG. The best performing algorithm, based upon a computer model of local and global brain 
networks, achieved nearly 60% sensitivity given 100% specificity and more than 60% specificity 
given 100% sensitivity. We assessed performance in this manner since an ideal screening test to use 
in a non-specialist setting needs 100% sensitivity to ensure all people with IGE are captured, but 
some false-positives are tolerable; whereas a decision support tool in the specialist setting needs 
100% specificity to avoid false-positives, but less than perfect sensitivity can be compensated for by 
further expert-driven evaluation.  
 
The use of routinely acquired EEG data, combined with minimal computational cost for evaluating 
the biomarker, makes this an attractive proposition from the perspective of clinical decision support. 
At present, the most time-consuming part is visual identification of “resting-state” EEG, which in 
our study was performed by a trained EEG technician. Automating this process, would permit 
delivery of a result in real-time (potentially whilst EEG was still being collected). A critical 
advantage of this method is that there is no requirement to observe epileptiform discharges in EEG 
to make a diagnosis, since the method relies only on brief segments of “resting-state” EEG. This 
yields the potential for a screening service to be offered in a non-specialist primary care 
environment, a resource-poor setting, or even using non-specialist EEG carried out in the patient’s 
home.  
 
Whilst these results are promising, it is important to note potential confounds that may limit the 
sensitivity and specificity achievable. Of note, cortical excitability (and by assumption seizure 
likelihood) is known to vary according to time of day; varying in response to both physiological 
factors and external stimuli11. It has very recently been shown that endocrine activity displays the 
strongest relationship with this circadian change12. In this study, most recordings were taken in the 
late morning or early afternoon and we found no significant difference (Wilcoxon test: p=1, t-test: 
p=0.758) in the times when recordings were taken and whether a subject was correctly classified 
(mean time – 12:52 +/- 1:36) or not (mean time – 12:38 +/- 2:19). 
The full code written in MATLAB13 can be found online14. 
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